Evidence map›Paper›PMID 41963592›Full record

ArticleLeukemia2026

Overcoming MEN1-mediated resistance with menin inhibitor switching in KMT2A-rearranged acute myeloid leukemia.

Kuo-Kai Chin, Maher Abdul-Hay, Mihir Shukla, Mark B Geyer, Roni Tamari, Kaitlyn H Ko, Wenbin Xiao, Eytan M Stein, Sheng F Cai

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Leukemia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Kuo-Kai Chin *Leukemia Service, Division of Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID http://orcid.org/0000-0003-4504-398X
Maher Abdul-Hay *Division of Hematology & Medical Oncology, Perlmutter Cancer Center at NYU Langone Health, New York, NY, USA.ORCID http://orcid.org/0000-0003-1041-7689
Mihir ShuklaDivision of Hematology & Medical Oncology, Perlmutter Cancer Center at NYU Langone Health, New York, NY, USA.
Mark B GeyerLeukemia Service, Division of Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID http://orcid.org/0000-0001-5248-9117
Roni TamariBone Marrow Transplant Service, Division of Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID http://orcid.org/0000-0002-2386-0850
Kaitlyn H KoLeukemia Service, Division of Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Wenbin XiaoDepartment of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID http://orcid.org/0000-0001-8586-8500
Eytan M Stein *Leukemia Service, Division of Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Sheng F Cai *Leukemia Service, Division of Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY, USA. cais1@mskcc.org.ORCID http://orcid.org/0000-0002-2708-887X

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID41963592
PMCPMC13233292

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.